San Raffaele Telethon Institute for Gene Therapy (SR-Tiget)
Silvia Gregori, PhD, is a Group Leader at the San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS Ospedale San Raffaele, Milan. Silvia Gregori was originally trained in cell and molecular biology and received her PhD from the University of Milan. After a short period in UK working on type 1 diabetes, she took a position at Roche Milano Ricerche with Prof. L. Adorini. During this period, she made important contributions unraveling networks of immunological tolerance, first by dissecting the role of Vitamin D3 and its analogues in modulating T cell responses in diabetes and in islet transplantation. In 2001, she took a postdoctoral position in the group led by Prof. MG. Roncarolo at SR-Tiget, where she elucidated new mechanisms of suppression mediated by T regulatory type 1 (Tr1) cells and identified DC-10 as major subset of dendritic cells involved in Tr1 cell differentiation. Currently she leads a research team that focuses on the development of efficient therapeutic approaches to (re)-establish antigen-specific tolerance based on the use of in vitro generated tolerogenic DC as medicinal product. Beside this main project, she is also supervising a number of projects aim at better understanding and modulating immune responses and tolerance to specific antigens/transgenes in pre-clinical and clinical settings.